Patents by Inventor Lawrence David Wise

Lawrence David Wise has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclohexylamine derivative as subtype selective NMDA receptor antagonists
    Patent number: 6919377
    Abstract: Described are compounds of Formula I and Formula II and their pharmaceutically acceptable salts. The compounds of Formulas I and II are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's disease.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: July 19, 2005
    Assignee: Warner Lambert Company LLC
    Inventors: Russell Joseph Deorazio, Sham Shridhar Nikam, Ian Leslie Scott, Brian Alan Sherer, Lawrence David Wise
  • Bicyclic cyclohexylamines and their use as NMDA receptor antagonists
    Patent number: 6794402
    Abstract: Described are bicycle-substituted cyclohexylamines of Formula I and their pharmaceutically acceptable salts thereof: The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's disease. The substituents are defined in the specification.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: September 21, 2004
    Assignee: Warner-Lambert Company
    Inventors: Sham Shridhar Nikam, Ian Leslie Scott, Brian Alan Sherer, Lawrence David Wise
  • Cyclohexylamine derivatives as subtype selective nmda receptor antagonists
    Patent number: 6765022
    Abstract: Described are cyclobexylamine derivatives of Formula I, Formula II, or Formula III and their pharmaceutically acceptable salts thereof: The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's disease. The substituents are described in the specification.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: July 20, 2004
    Assignee: Warner-Lambert Company
    Inventors: Russell Joseph Deorazio, Sham Shridhar Nikam, Ian Leslie Scott, Brian Alan Sherer, Lawrence David Wise
  • Mono-and disubstituted 3-propyl gamma-aminobutyric acids
    Publication number: 20040063789
    Abstract: The instant invention is a series of novel mono- and disubstituted 3-propyl gamma aminobutyric acids of Formula I 1
    Type: Application
    Filed: September 29, 2003
    Publication date: April 1, 2004
    Inventors: Thomas Richard Belliotti, Justin Stephen Bryans, Ihoezo Victor Ekhato, Augustine Tobi Osuma, Robert Michael Schelkun, Jacob Bradley Schwarz, Andrew John Thorpe, Lawrence David Wise, David Juergen Wustrow, Po-Wai Yuen
  • Bicyclic cyclohexylamines and their use as NMDA receptor antagonists
    Patent number: 6683101
    Abstract: Described are heterocycle-substituted cyclohexylamines of formula (I), and their pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: January 27, 2004
    Assignee: Warner-Lambert Company
    Inventors: Russell Joseph Deorazio, Sham Shridhar Nikam, Ian Leslie Scott, Brian Alan Sherer, Lawrence David Wise
  • Bicyclic cyclohexylamines and their use as nmda receptor antagonists
    Publication number: 20030236252
    Abstract: Described are bicycle-substituted cyclohexylamines of Formula (I) and their pharmaceutically acceptable salts thereof. The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's specification. disease. The substituents are defined in the specification.
    Type: Application
    Filed: November 12, 2002
    Publication date: December 25, 2003
    Inventors: Sham Shridhar Nikam, Ian Leslie Scott, Brian Alan Sherer, Lawrence David Wise
  • Cyclohexylamine derivative as subtype selective nmda receptor antagonists
    Publication number: 20030236286
    Abstract: Described are compounds of Formula I and Formula II and their pharmaceutically acceptable salts. The compounds of Formulas I and II are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's disease.
    Type: Application
    Filed: October 25, 2002
    Publication date: December 25, 2003
    Inventors: Russell Joseph Deorazio, Sham Shridhar Nikam, Ian Leslie Scott, Brian Alan Sherer, Lawrence David Wise
  • Bicyclic cyclohexylamines and their use as nmda receptor antagonists
    Publication number: 20030232810
    Abstract: Described are heterocycle-substituted cyclohexylamines of formula (I), and their pharmaceutically acceptable salts thereof. The compounds of formula (I) are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's disease.
    Type: Application
    Filed: December 3, 2002
    Publication date: December 18, 2003
    Inventors: Russell Joseph Deorazio, Sham Shridhar Nikam, Ian Leslie Scott, Brian Alan Sherer, Lawrence David Wise
  • Cyclohexylamine derivatives as subtype selective nmda receptor antagonists
    Publication number: 20030225164
    Abstract: Described are cyclohexylamine derivatives of Formula (I), Formula (II) or Formula (III) and their pharmaceutically acceptable salts thereof. The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's disease. The substituents are described in the specification.
    Type: Application
    Filed: December 2, 2002
    Publication date: December 4, 2003
    Inventors: Russell Joseph Deorazio, Sham Shridhar Nikam, Ian Leslie Scott, Brian Alan Sherer, Lawrence David Wise
  • Mono-and disubstituted 3-propyl gamma-aminobutyric acids
    Patent number: 6642398
    Abstract: The instant invention is a series of novel mono- and disubstituted 3-propyl gamma aminobutyric acids of Formula I The compounds are useful as therapeutic agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, arthritis, sleep disorders, IBS, and gastric damage. Methods of preparing the compounds and useful intermediates are also part of the invention.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: November 4, 2003
    Assignee: Warner-Lambert Company
    Inventors: Thomas Richard Belliotti, Justin Stephen Bryans, Ihoezo Victor Ekhato, Augustine Tobi Osuma, Robert Michael Schelkun, Jacob Bradley Schwarz, Andrew John Thorpe, Lawrence David Wise, David Juergen Wustrow, Po-Wai Yuen
  • Mono-and disubstituted 3-propyl gamma-aminobutyric acids
    Publication number: 20030181523
    Abstract: The instant invention is a series of novel mono- and disubstituted 3-propyl gamma aminobutyric acids of Formula I 1
    Type: Application
    Filed: December 20, 2002
    Publication date: September 25, 2003
    Inventors: Thomas Richard Belliotti, Justin Stephen Bryans, Ihoezo Victor Ekhato, Augustine Tobi Osuma, Robert Michael Schelkun, Jacob Bradley Schwarz, Andrew John Thorpe, Lawrence David Wise, David Juergen Wustrow, Po-Wai Yuen
  • Hexahydro-naphthalenone oximes and hydrazones
    Patent number: 6187808
    Abstract: This invention provides 6-amino-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one oximes and hydrazones which are useful in treating Parkinson's disease.
    Type: Grant
    Filed: September 27, 1999
    Date of Patent: February 13, 2001
    Assignee: Warner-Lambert Company
    Inventors: Stephen Joseph Johnson, Leonard Theodore Meltzer, Lawrence David Wise
  • Method of treating psychosis and schizophrenia
    Patent number: 6051605
    Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors, and to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors.
    Type: Grant
    Filed: January 29, 1999
    Date of Patent: April 18, 2000
    Assignee: Warner-Lambert Company
    Inventors: Thomas Capiris, David Thomas Connor, Steven Robert Miller, Paul Charles Unangst, Lawrence David Wise
  • Compounds and method of treating psychosis and schizophrenia
    Patent number: 6020364
    Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors, and to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: February 1, 2000
    Assignee: Warner-Lambert Company
    Inventors: David Thomas Connor, Stephen Joseph Johnson, Suzanne Ross Kesten, Steven Robert Miller, Paul Charles Unangst, Lawrence David Wise
  • Dopamine D4 receptor antagonists
    Patent number: 5945421
    Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors, to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors, and to pharmaceutically acceptable compositions that contain a dopamine D4 receptor antagonist.
    Type: Grant
    Filed: August 11, 1997
    Date of Patent: August 31, 1999
    Assignee: Warner-Lambert Company
    Inventors: Thomas Richard Belliotti, Clifton John Blankley, Suzanne Ross Kesten, Lawrence David Wise, David Juergen Wustrow
  • Coumarin dopamine D4 receptor antagonists
    Patent number: 5922719
    Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors, to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors, and to pharmaceutically acceptable compositions that contain a dopamine D4 receptor antagonist.
    Type: Grant
    Filed: August 11, 1997
    Date of Patent: July 13, 1999
    Assignee: Warner-Lambert Company
    Inventors: Stephen Joseph Johnson, Suzanne Ross Kesten, Lawrence David Wise, David Juergen Wustrow
  • Compounds and method of treating psychosis and schizophrenia
    Patent number: 5916914
    Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors, and to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: June 29, 1999
    Assignee: Warner-Lambert Company
    Inventors: David Thomas Connor, Stephen Joseph Johnson, Suzanne Ross Kesten, Steven Robert Miller, Paul Charles Unangst, Lawrence David Wise
  • Antipsychotic method utilizing certain tetrahydrochromeno?3,4-c!pyridin-5-ones
    Patent number: 5760050
    Abstract: 1,2,3,4-Tetrahydro-chromeno?3,4-c!pyridin-5-ones of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.5 include hydrogen, alkyl, alkoxy, hydroxy, halo, nitro, amino, and trifluoromethyl; R.sub.4 is unsubstituted or substituted phenyl, pyridyl, or quinolinyl; and n is 0 to 4, are useful to treat psychosis in mammals, particularly schizophrenia.
    Type: Grant
    Filed: February 27, 1997
    Date of Patent: June 2, 1998
    Assignee: Warner-Lambert Company
    Inventors: David Thomas Connor, Steven Robert Miller, Paul Charles Unangst, Lawrence David Wise